Tezepelumab in Canadian Adults With Severe Chronic Rhinosinusitis With Nasal Polyps: A Subgroup Analysis of the Phase 3 WAYPOINT Trial.
IMPORTANCE Tezepelumab, a monoclonal antibody targeted against thymic stromal lymphopoietin, was recently approved in Canada for the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). Its effectiveness specifically in the Canadian setting has not been evaluated. OBJECTIVE To analyze t...